Company Analysis

Forte Biosciences, Inc. (FBRX)

FBRX · Pharmaceutical Preparations · Dallas, TX · filing with the SEC since 2007
Grade4.8
◀ Past 3.3● Present 3.7▶ Future 6.8
2 est.

Who runs Forte Biosciences, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Wagner Paul A.
CEO, Secretary and Chair of the Board. First filing Jun 2020, latest Aug 27, 2026, 8 filings in all.
Officers reporting now
2
of 9 people with a filing in the last fifteen months
Directors reporting now
7
26 people on the record since 2017
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Wagner Paul A.CEO, Secretary and Chair of the BoardJun 2020Aug 27, 2026none
Riley Antony ACHIEF FINANCIAL OFFICERJun 2020Aug 27, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Brun Scott C.directorNov 2022Aug 27, 2026none
Doberstein Stephen KdirectorMay 2022Aug 27, 2026none
Finck Barbara KdirectorMar 2022Aug 27, 2026none
Gryska David WdirectorJan 2023Aug 27, 2026none
Kapoor Shivpreet SinghdirectorSep 2024Aug 27, 2026none
Kornfeld StevendirectorJun 2020Aug 27, 2026none
Vincent Richard GdirectorSep 2024Aug 27, 2026none
Earlier names on the record18, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton FBRX · research, not advice